Novartis Holds Lead In Oral MS Space With Fingolimod Filing
Executive Summary
Novartis has gained the lead in the race to market for the first oral therapy for multiple sclerosis with the NDA submission for fingolimod, a feat made possible by FDA's refusal to file the earlier NDA for Merck Serono's oral MS candidate cladribine
You may also be interested in...
If Novartis's Gilenia Clears Safety Hurdle, Other Oral MS Drugs May Have An Easier Path
While fingolimod has a broadly similar safety profile to Merck Serono's cladribine and Teva's laquinimod, additional cardiac, pulmonary and ophthalmic adverse events may give Novartis's first mover a higher barrier to clear.
Novartis Talking About Fingolimod Safety With FDA; Will Talk To Advisory Panel In June
Structure of the REMS for oral multiple sclerosis drug Gilenia likely to be discussed at committee meeting close to review deadline.
Despite Ocrelizumab Infection Risk, Roche Sees Multiple Sclerosis Opportunity
Anti-CD20 molecule's future in RA was dashed by high infection risk, but Roche says the safety profile of ocrelizumab could be better in MS patients.